Daptomycin should not be used to treat pneumonia because it is inactivated by pulmonary surfactant.

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $9.99Unlock all

Prepare for the Antibacterials (ABX) Exam. Study with flashcards and multiple-choice questions, each question comes with hints and explanations. Get ready to ace your test!

Multiple Choice

Daptomycin should not be used to treat pneumonia because it is inactivated by pulmonary surfactant.

Explanation:
Daptomycin is a calcium-dependent lipopeptide that disrupts the Gram-positive bacterial membrane and is highly active against MRSA and VRE. It is approved for complicated skin and soft tissue infections and for bacteremia, including right-sided endocarditis. However, pulmonary surfactant inactivates daptomycin, preventing it from reaching or killing bacteria in the lungs. Because of this, it should not be used to treat pneumonia. Other contexts like bacteremia, skin and soft tissue infections, or endocarditis are appropriate for daptomycin, but pneumonia is not due to the surfactant-driven inactivation.

Daptomycin is a calcium-dependent lipopeptide that disrupts the Gram-positive bacterial membrane and is highly active against MRSA and VRE. It is approved for complicated skin and soft tissue infections and for bacteremia, including right-sided endocarditis. However, pulmonary surfactant inactivates daptomycin, preventing it from reaching or killing bacteria in the lungs. Because of this, it should not be used to treat pneumonia. Other contexts like bacteremia, skin and soft tissue infections, or endocarditis are appropriate for daptomycin, but pneumonia is not due to the surfactant-driven inactivation.

More Multiple Choice Questions
Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy